Omeros Corporation reported $91M of revenue over the trailing twelve months. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $91M (to Q3 2021). Net income: $125M, trailing twelve months to Q2 2026. Free cash flow: −$69M, trailing twelve months to Q2 2026. EPS: $1.72, trailing twelve months to Q2 2026.

OMEROmeros Corporation

Healthcare

$10.72+217% 1Y

$10.72

$4.1052 weeks$21.04

OMER as reported

Omeros Corporation reported $91M of revenue over the trailing twelve months. 10 reported series are charted on this page, each one as filed.

$91M

Revenue, trailing twelve months · to Q3 2021 · every figure below is as filed, with no scoring applied

Net income: $125M
Net income · −202% year on year · trailing twelve months to Q2 2026
Free cash flow: −$69M
Free cash flow · −42% year on year · trailing twelve months to Q2 2026
EPS: $1.72
EPS · −181% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for OMER, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$91M	n/a	Q3 2021 · 19 quarters behind
Net income	$125M	−202%	Q2 2026
EPS	$1.72	−181%	Q2 2026
Gross margin	99%	n/a	Q3 2021 · 19 quarters behind
Operating margin	−206%	n/a	Q3 2021 · 19 quarters behind
Net margin	−173%	n/a	Q3 2021 · 19 quarters behind
ROE	−80%	n/a	Q2 2026
ROA	1.8%	n/a	Q2 2026
ROIC	95%	n/a	Q4 2025
Free cash flow	−$69M	−42%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.